Nicholas Neveling

Medtech moves into private equity’s sweet spot

Lower valuations, corporate carve-outs and resilience to AI disruption are opening up medtech to buyout firms after years of limited access.

Manager due diligence 2.0 is already here

AI is well on its way to reshaping how LPs evaluate PE funds, but as the technology becomes increasingly widespread, it’s data quality and human judgment that are emerging as key factors.

LPs adjust their approach to secondaries

Secondaries are evolving from a problem-solving backstop into a strategic tool for LPs navigating liquidity constraints and portfolio complexity.

LPs fine-tune their use of secondaries

Secondaries are evolving from a problem-solving backstop into a strategic tool for North American LPs navigating liquidity constraints and portfolio complexity.

GPs face up to PE’s valuations problem

As demand for distributions rises, PE managers may have to take a more pragmatic approach to pricing in the months ahead.

M&A reshapes the GP stakes galaxy

Rising consolidation in the PE industry means both more competition for attractive targets and more opportunities for exits.

How CV dealmakers are addressing LPs’ process pain points

GP-led deal volume hit an all-time high in 2025, but record growth doesn’t necessarily equate to LP satisfaction with continuation vehicle processes.

Investors remain vigilant amid macro uncertainty

LPs are keeping a close eye on trade and tariff developments, but are not changing their allocation strategies and investment portfolio mix yet.

How to find and hire specialist private wealth talent

For most GPs, tapping into the growing pool of private wealth capital requires a different set of in-house capabilities, prompting some aggressive recruitment drives.

LPs drill down into GPs’ long-term resilience

When it comes to fund due diligence in an uncertain market, investors are upping their focus on commercial fundamentals and talent plans.